University Hospital Brno

Brno 639 00

6 studies enrolling now · 49 studies all time

What they study most

ALK-positive Histiocytosis, ATRT Recurrent, Acute Ischemic Stroke, Acute Myeloid Leukemia, Acute Myocardial Infarction, Adenocarcinoma of the Esophagus, Age-Related Macular Degeneration, Atrial Flutter, B-Cell Chronic Lymphocytic Leukemia (B-CLL), B-cell Non-Hodgkin's Lymphoma, Cerebrospinal Fluid Leak, Chronic Hepatitis C Infection

Studies at this site

• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors — Recruiting now
• International Rare Histiocytic Disorders Registry (IRHDR) — Recruiting now
• GEN1046 Safety Trial in Patients With Malignant Solid Tumors — Running, not enrolling
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] — Completed
• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma — Completed
• A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer — Running, not enrolling
• Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) — Completed
• A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI — Running, not enrolling
• Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Running, not enrolling
• Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia — Completed
• Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF — Completed
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML — Completed
• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL — Completed
• A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) — Completed
• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA — Stopped early
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure — Completed
• Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer — Stopped early
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) — Completed
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) — Completed
• Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma — Stopped early
• An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy — Stopped early
• Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) — Completed
• Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) — Completed
• Observational Study of OCT in a Patients Undergoing FFR — Completed
• Safety of Dabigatran Etexilate in Blood Clot Prevention in Children — Completed
• RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism — Completed
• A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma — Completed
• This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) — Completed
• Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed
• Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus — Completed
• Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. — Completed
• Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke — Stopped early
• Fractional Flow Reserve (FFR) Versus Instant Wave-Free Ratio (iFR) — Completed